Neurocrine Biosciences Stock Forecast
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
NBIX analyst consensus
Consensus (29 analysts)
strong_buy
Avg. price target
$207.29+46.75%
- Strong buy 4
- Buy 21
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 29 Wall Street analysts covering Neurocrine Biosciences (2026-10-08), 25 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $207.29, with a high estimate of $253.00 and a low estimate of $164.00. The average target implies upside of 46.8% from the current price of $141.25.
The spread between the highest and lowest targets is 54.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NBIX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 14% |
| Buy | 21 | 72% |
| Hold | 4 | 14% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $164.00 | +16.11% |
| Average target | $207.29 | +46.75% |
| High target | $253.00 | +79.12% |